David Cook, MD

• Degrees:
  BS - University of Notre Dame, 1959
  MD - St. Louis University, 1963
• Residency:
  Internal Medicine - University of Chicago and Mayo Clinic, 1964-65 and 1967-69
• Fellowship:
  Smith, Kline, and French Foreign Fellowship - Sisters of Mercy Hospital, India, 1962
  USPHS Training Fellowship in Endocrinology University of Oregon Medical School 1969-71
  Fogarty International Fellowship National Institute of Health 1980-81

• Biosketch:
  Dr. David Cook has been involved in clinical and laboratory research since 1969. In collaboration with Dr. Kendall and Dr. Leslie Rees, St. Bartholomew's Hospital London, England, the first clinically useful assay for plasma ACTH was developed. Since that time publications and research have been focused on pituitary-adrenal clinical problems, especially Cushing's Syndrome and Cushing's Disease. Dr. Cook's clinical interest has included other pituitary problems, including those of too much and too little growth hormone and the impact of these clinical metabolic derangements which include acromegaly and the adult growth hormone deficiency syndrome. The clinical usefulness of cavernous sinus sampling of plasma ACTH for the differential diagnosis of ACTH dependent Cushing's syndrome is one of the products of his interest. More recently, dosing of growth hormone for adults deficient in these hormones has been another focus. National collaborative studies include treatment of acromegalic patients with long acting somatostatin analogues and problems in the diagnosis of growth hormone deficiency in adults.
• Recent Publications:
  

  Gharib H, Cook DM, Saenger PH, Bengtsson BA, Feld S, Nippoldt TB, Rodbard HW, Seibel JA, Vance ML, Zimmerman D, Palumbo PJ, Bergman DA, Garber JR, Hamilton CR Jr, Petak SM, Rettinger HI, Service FJ, Shankar TP, Stoffer SS, Tourletot JB; American Association of Clinical Endocrinologists Growth Hormone Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for growth hormone use in adults and children--2003 update. Endocr Pract. 2003 Jan-Feb;9(1):64-76.

  Cook DM, Biller BM, Vance ML, Hoffman AR, Phillips LS, Ford KM, Benziger DP, Illeperuma A, Blethen SL, Attie KM, Dao LN, Reimann JD, Fielder PJ. The pharmacokinetic and pharmacodynamic characteristics of a long-acting growth hormone (GH) preparation (nutropin depot) in GH-deficient adults. J Clin Endocrinol Metab. 2002 Oct;87(10):4508-14.

  Cook DM. Related Articles, Links Shouldn't adults with growth hormone deficiency be offered growth hormone replacement therapy? Ann Intern Med. 2002 Aug 6;137(3):197-201.

  Biller BM, Samuels MH, Zagar A, Cook DM, Arafah BM, Bonert V, Stavrou S, Kleinberg DL, Chipman JJ, Hartman ML. Sensitivity and specificity of six tests for the diagnosis of adult GH deficiency. J Clin Endocrinol Metab. 2002 May;87(5):2067-79.

  van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Vance ML, Freda PU, Stewart PM, Friend KE, Clemmons DR, Johannsson G, Stavrou S, Cook DM, Phillips LS, Strasburger CJ, Hackett S, Zib KA, Davis RJ, Scarlett JA, Thorner MO. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet. 2001 Nov 24;358(9295):1754-9.

• All Publications